SAN DIEGO, December 1, 2022 – Meet Antonius Schuh, Ph.D. (CEO), and Steve Zaniboni (CFO) for an update on selectION’s clinical work in atopic dermatitis.
Site Search
Recent News
- selectION Demonstrates Safety and Disease-Modifying Mechanism of Action of its Investigational Drug, si-544, in Phase 1b Proof-of- Concept Trial in Psoriasis, a T Cell-Mediated Autoimmune Disease
- Congratulations to our Scientific Advisor, Dr. Fred Ramsdell, for receiving the 2025 Nobel Prize in Physiology.
- Meet selectION, Inc. at BIO International Convention in Boston,MA, on June 16th-19th, 2025